Cervical cancer - Pipeline Insight, 2021
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Cervical cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Cervical cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cervical cancer: Overview
Cervical cancer develops in a woman's cervix (the entrance to the uterus from the vagina). Almost all Cervical cancer cases (99%) are linked to infection with high-risk human papillomaviruses (HPV), an extremely common virus transmitted through sexual contact. Although most infections with HPV resolve spontaneously and cause no symptoms, persistent infection can cause Cervical cancer in women. Cervical cancer is the fourth most common cancer in women. In 2018, an estimated 570 000 women were diagnosed with Cervical cancer worldwide and about 311 000 women died from the disease. Effective primary (HPV vaccination) and secondary prevention approaches (screening for, and treating precancerous lesions) will prevent most Cervical cancer cases. When diagnosed, Cervical cancer is one of the most successfully treatable forms of cancer, as long as it is detected early and managed effectively. Cancers diagnosed in late stages can also be controlled with appropriate treatment and palliative care.
'Cervical cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cervical cancer pipeline landscape is provided which includes the disease overview and Cervical cancer treatment guidelines. The assessment part of the report embraces, in depth Cervical cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cervical cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Cervical cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cervical cancer Emerging Drugs
Further product details are provided in the report……..
Cervical cancer: Therapeutic Assessment
This segment of the report provides insights about the different Cervical cancer drugs segregated based on following parameters that define the scope of the report, such as:
Cervical cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cervical cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cervical cancer drugs.
Cervical cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Cervical cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Cervical cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cervical cancer: Overview
Cervical cancer develops in a woman's cervix (the entrance to the uterus from the vagina). Almost all Cervical cancer cases (99%) are linked to infection with high-risk human papillomaviruses (HPV), an extremely common virus transmitted through sexual contact. Although most infections with HPV resolve spontaneously and cause no symptoms, persistent infection can cause Cervical cancer in women. Cervical cancer is the fourth most common cancer in women. In 2018, an estimated 570 000 women were diagnosed with Cervical cancer worldwide and about 311 000 women died from the disease. Effective primary (HPV vaccination) and secondary prevention approaches (screening for, and treating precancerous lesions) will prevent most Cervical cancer cases. When diagnosed, Cervical cancer is one of the most successfully treatable forms of cancer, as long as it is detected early and managed effectively. Cancers diagnosed in late stages can also be controlled with appropriate treatment and palliative care.
'Cervical cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cervical cancer pipeline landscape is provided which includes the disease overview and Cervical cancer treatment guidelines. The assessment part of the report embraces, in depth Cervical cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cervical cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cervical cancer R&D. The therapies under development are focused on novel approaches to treat/improve Cervical cancer.
This segment of the Cervical cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cervical cancer Emerging Drugs
- Cemiplimab: Regeneron Pharmaceuticals
- AK104: Akesobio
- Durvalumab: Celgene
Further product details are provided in the report……..
Cervical cancer: Therapeutic Assessment
This segment of the report provides insights about the different Cervical cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cervical cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Cervical cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cervical cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cervical cancer drugs.
Cervical cancer Report Insights
- Cervical cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cervical cancer drugs?
- How many Cervical cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cervical cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cervical cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cervical cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Regeneron Pharmaceuticals
- Akesobio
- Celgene
- AstraZeneca
- ImaginAb Inc
- Genexine, Inc.
- Merck KGaA
- Seagen Inc.
- Vaccibody AS
- Qilu Pharmaceutical Co., Ltd.
- Genor Biopharma Co., Ltd.
- Agenus Inc.
- Immunitor LLC
- Genentech
- Guangzhou Gloria Biosciences Co., Ltd.
- Lee's Pharmaceutical Limited
- BeiGene
- Henlix Biotech
- Biocad
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Cellid Co., Ltd.
- Innovent Biologics
- Zeria Pharmaceutical
- Advaxis, Inc.
- Human Genome Sciences
- Hookipa Biotech GmbH
- Eli Lilly and Company
- SK Bioscience Co., Ltd.
- Tesaro, Inc
- Iovance Biotherapeutics, Inc.
- NETRIS Pharma
- Advenchen Laboratories, LLC
- Rubius Therapeutics
- Repertoire Immune Medicines
- Bristol-Myers Squibb
- Sotio a.s.
- VM Oncology, LLC
- Andes Biotechnologies
- Transgene
- Xencor, Inc.
- Exelixis
- Ocellaris Pharma, Inc
- Fate Therapeutics
- Arcus Biosciences, Inc.
- MacroGenics
- Cemiplimab
- AK104
- Durvalumab
- MEDI 0457
- 89Zr Df IAB 22M2C
- GX-188E
- M7824
- Tisotumab Vedotin
- VB10.16
- QL1604
- GB226
- AGEN2034
- V3-Cervix
- Tiragolumab
- GLS-010
- ZKAB001
- Tislelizumab
- HLX10
- BCD-100
- SG001
- BVAC-C
- IBI310
- Z-100
- ADXS11-001
- Mapatumumab
- HB-201
- Gemzar
- NBP615
- Niraparib
- LN-145
- NP137
- AL3818
- RTX-321
- RPTR-168
- BMS-986340
- SO-C101
- VMD-928
- Andes-1537
- TG4001
- XmAb®23104
- XB002
- OC-001
- FT 500
- AB308
- MGD013
Introduction
Executive Summary
Cervical cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Cemiplimab: Regeneron Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AK104: Akeso Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
TG4001: Transgene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
IMGN 151: ImmunoGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cervical cancer Key Companies
Cervical cancer Key Products
Cervical cancer- Unmet Needs
Cervical cancer- Market Drivers and Barriers
Cervical cancer- Future Perspectives and Conclusion
Cervical cancer Analyst Views
Cervical cancer Key Companies
Appendix
Executive Summary
Cervical cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Cemiplimab: Regeneron Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AK104: Akeso Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
TG4001: Transgene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
IMGN 151: ImmunoGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Cervical cancer Key Companies
Cervical cancer Key Products
Cervical cancer- Unmet Needs
Cervical cancer- Market Drivers and Barriers
Cervical cancer- Future Perspectives and Conclusion
Cervical cancer Analyst Views
Cervical cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Cervical cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cervical cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cervical cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cervical cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
